ArticleNeurochemical research2026
SVHRSP Attenuates PTZ-Induced Seizure-Like Behavior in C. elegans: Involvement of HSF-1 and Associated Changes in GABAergic Markers and Mitochondrial Homeostasis.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Epilepsy is a prevalent neurological disorder. Nevertheless, approximately one-third of patients fail to achieve sufficient seizure control through current pharmacological treatments. This unmet need underscores the importance of developing new antiseizure treatments for drug-resistant epilepsy. Scorpion venom heat-resistant synthetic peptide (SVHRSP), which is derived from scorpion venom and chemically synthesized, has demonstrated promising activity against acute PTZ-evoked seizure-like behaviors. In this study, the effects of SVHRSP pretreatment on acute PTZ-evoked seizure-like behavior were evaluated in Caenorhabditis elegans. Our findings indicate that SVHRSP (50 μM) significantly alleviated the seizure-like behavioral symptoms induced by PTZ (30 mg/mL). Specifically, behavioral assessments showed that SVHRSP improved survival and attenuated PTZ-associated deficits in locomotion, food preference, chemotaxis, and pharyngeal pumping in PTZ-exposed nematodes. Furthermore, SVHRSP pretreatment partially reversed PTZ-associated changes in GABAergic and glutamatergic reporter fluorescence and in the transcript abundance of unc-25, gat-1, and eat-4. SVHRSP also ameliorated mitochondrial dysfunction and reduced oxidative stress. SVHRSP pretreatment was also associated with increased ced-9 transcript abundance, reduced cep-1 transcript abundance, lower intracellular ferrous iron (Fe
Indexed as
Identifiers
42726187What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.